AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for July 17, 2019 meeting

IV. Secretary’s report

V. Old Business
   A. WellCare and Amerigroup breakdown of “other category” in the quarterly PA Denials Report
   B. Horizon’s absolute denials (percentage of denials not reversed) in “clinical criteria not met” category

VI. New Business
   A. Proposed protocol for hereditary transthyretin-mediated amyloidosis (hATTR) products
   B. Proposed protocol Elaprase® (idursulfase)
   C. Proposed protocol for Gaucher disease products
   D. Proposed protocol for Cablivi® (caplacizumab-yhdp)

VII. DURB Annual Report for SFY 2019 (July 1, 2018 thru June 30, 2019) – Board members packet

VIII. A. Informational Highlights/Reports
       1. DXC Technology/NJ HMO 2nd Quarter 2019 Prior Authorization Report
       2. Summary of DURB Action Items
       3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
          (b) Physician-administered/Antiviral drugs by amount paid

       B. Medication information:
          (a) FDA says widening probe on generic drug impurities
          (b) Combination benzodiazepine, antidepressant use during pregnancy warrants caution
          (c) PPI Use in Infants With Acid Reflux Increases Early Fracture Risks
          (d) CMS gives states, MCOs guidance on tracking Medicaid opioid use
          (e) Study finds about 1 in 7 people with diabetes ration medicine due to cost

IX. Referenced Materials
    A. Approved protocol for Urea Cycle Disorder products
    B. Approved protocol for Zolgensma (onasemnogene abeparvovec-xioi)
    C. Approved protocol for Cuprimine® (penicillamine) and Syprine® (trientine) Used in the Treatment of
       Wilson’s Disease, Cystinuria, and Severe, Active Rheumatoid Arthritis